Search

everythinglearnresearchcommunity

for

Search:↓

Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil, questioning the effectiveness and safety of continuing RU58841. They experienced hair loss improvement initially but are now considering stopping RU58841 due to cost and safety concerns.

The user tried various hair loss treatments, including Maxogen-X, Dualgen15, minoxidil, finasteride, and dermarolling, but experienced limited regrowth and some side effects. They eventually switched to oral minoxidil, hoping for better results.

The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.

The user has been using topical finasteride and minoxidil for 5 years, with recent use of a liposomal formulation, but sees no significant improvement. They are considering switching to oral treatments due to continued hair loss and thinning.

The user is exploring KX-826 as a potential hair loss treatment due to intolerance to FDA-approved drugs like Minoxidil and finasteride. They seek fundamental help and information about KX-826.

OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The conversation discusses finding a reliable source for liposomal finasteride. The user currently uses a topical product with Minoxidil, finasteride, retinoic acid, and hydrocortisone, and is considering MinoxidilMax's Maxogen-x.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.

The conversation is about a user who had a hair transplant with 2,850 grafts and switched from finasteride and topical minoxidil to oral minoxidil and dutasteride for better results. They are hopeful for full results in a year.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

The conversation discusses the use of topical finasteride and minoxidil for hair loss and inquires about the effectiveness of adding RU58841. Participants share experiences and opinions on the potential benefits of including RU58841 in their treatment regimen.

The user transitioned from finasteride to RU58841 and oral minoxidil to maintain hair gains while avoiding systemic DHT suppression. They have not experienced increased shedding or side effects since stopping finasteride and hope RU58841 will preserve their hair.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

A user shared their one-month progress using Minoxidil and RU58841 for hair loss, noting significant shedding after micro-needling and seeking opinions on their regrowth. They stopped micro-needling and added RU58841 to their treatment.

RU58841 users discuss increasing dosage for better hair regrowth, with some considering adding minoxidil and finasteride. Users report mixed results, with some experiencing side effects at higher doses.

The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.

PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.